CoChat

Comparison of the anti‐diabetic effects of GIP‐ and GLP‐1‐receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N‐AcGIP and exendin(1–39)amide

Irwin, Nigel, McClean, Paula L., Cassidy, Roslyn S., O'Harte, Finbarr P. M., Green, Brian D., Gault, Victor A., Harriott, Patrick, Flatt, Peter R. · 2007 · Diabetes/Metabolism Research and Reviews
Cited by 32

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background: The two major incretin hormones, glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are being actively explored as anti‐diabetic agents because they lower blood glucose through multiple mechanisms. The rapid inactivation of GIP and GLP‐1 by the ubiquitous enzyme, dipeptidyl peptidase IV (DPP IV) makes their biological actions short‐lived, but stable agonists such as N‐acetylated GIP (N‐AcGIP) and exendin(1‐39)amide have been advocated as stable and specific GIP and GLP‐1 analogues. Methods: The present study examined the sub‐chronic (14 days) anti‐diabetic actions of single daily doses of N‐AcGIP and exendin(1‐39)amide given alone or in combination to obese diabetic (ob/ob) mice over a 14‐day period. Results: Initial experiments confirmed the potent anti‐hyperglycaemic and insulinotropic properties of N‐AcGIP and exendin(1‐39)amide. Sub‐chronic administration of N‐AcGIP alone or in combination with exendin(1‐39)amide significantly decreased non‐fasting plasma glucose and improved glucose tolerance compared to control ob/ob mice. This was associated with a significant enhancement of the insulin response to glucose and a notable improvement of insulin sensitivity. Combined treatment with N‐AcGIP and exendin(1‐39)amide also significantly decreased glycated haemoglobin. Exendin(1‐39)amide alone had no significant effect on any of the metabolic parameters monitored. In addition, no significant effects were observed on body weight and food intake in any of the treatment groups. Conclusions: The results illustrate significant anti‐diabetic potential of N‐AcGIP alone and in combination with exendin(1‐39)amide. Copyright © 2007 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.729

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 32

Metadata

Authors
Irwin, N., McClean, P. L., Cassidy, R. S., O'Harte, F. P. M., Green, B. D., Gault, V. A., Harriott, P., & Flatt, P. R.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2007-02-21
Volume
23
Issue
7
Pages
572-579
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W2125364438
Cited by
32
References
8
FWCI
1.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of the anti‐diabetic effects of GIP‐ and GLP‐1‐receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N‐AcGIP and exendin(1–39)amide. https://app.cochat.ai/papers/10.1002/dmrr.729
The paper
Irwin, N., McClean, P. L., Cassidy, R. S., O'Harte, F. P. M., Green, B. D., Gault, V. A., Harriott, P., & Flatt, P. R. (2007). Comparison of the anti‐diabetic effects of GIP‐ and GLP‐1‐receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N‐AcGIP and exendin(1–39)amide. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.729

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.